Feste Formen von (s)-2-(((s)-6,8-Ifluor-1,2,3,4-Tetrahydronaphthalen-2-Yl)amino)-N-(1-(2-Methyl-1-(neopentylamino)propan-2-Yl)-1H-Imidazol-4-Yl)pentanamid und Verwendungen davon

Details

Veröffentlichungs-Nr.

EP4722197

Anmeldetag

9. August 2019

Veröffentlichung

8. April 2026

Rechtsraum

EP

IPC

(PFIZER PROD INC et al.)(UNIV RAMOT et al.)

Abstract

The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.

Anmelder

Firma

Pfizer Inc.

Land

🇺🇸 USA